169 related articles for article (PubMed ID: 2599802)
1. Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study.
Rowinsky EK; Grochow LB; Hantel A; Ettinger DS; Vito BL; Donehower RC
Invest New Drugs; 1989 Nov; 7(4):317-25. PubMed ID: 2599802
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity.
Rowinsky EK; Noe DA; Orr DW; Grochow LB; Ettinger DS; Donehower RC
J Natl Cancer Inst; 1988 Jul; 80(9):671-8. PubMed ID: 3373556
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of N-methylformamide (NMF, NSC 3051).
O'Dwyer PJ; Donehower M; Sigman LM; Fortner CL; Aisner J; Van Echo DA
J Clin Oncol; 1985 Jun; 3(6):853-7. PubMed ID: 4009219
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of N-methylformamide in patients with metastatic melanoma.
Eton O; Bajorin DF; Casper ES; Houghton AN
Invest New Drugs; 1991 Feb; 9(1):97-100. PubMed ID: 2026491
[TBL] [Abstract][Full Text] [Related]
5. N-Methylformamide in advanced squamous cancer of the uterine cervix: an Eastern Cooperative Oncology Group phase II trial.
Rajdev L; Yu ZF; Wadler S; Weller E; Kahn SB; Tormey D; Skeel R; Wiernik PH
Invest New Drugs; 2001; 19(3):233-7. PubMed ID: 11561680
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of N-methylformamide in advanced renal cancer.
Abrams JS; Tait N; Silva H; Eisenberger M; Van Echo DA; Olver IN; Aisner J
Am J Clin Oncol; 1989 Feb; 12(1):41-2. PubMed ID: 2912020
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of N-methylformamide in patients with advanced cancer.
Ettinger DS; Orr DW; Rice AP; Donehower RC
Cancer Treat Rep; 1985 May; 69(5):489-93. PubMed ID: 4005871
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of N-methylformamide in advanced head and neck cancer.
Vogel WC; Forastiere AA; Natale RB; Takasugi BJ; Schnur G
Invest New Drugs; 1987; 5(2):203-6. PubMed ID: 3654153
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.
Salazar R; Cortés-Funes H; Casado E; Pardo B; López-Martín A; Cuadra C; Tabernero J; Coronado C; García M; Soto Matos-Pita A; Miguel-Lillo B; Cullell-Young M; Iglesias Dios JL; Paz-Ares L
Cancer Chemother Pharmacol; 2013 Jul; 72(1):75-83. PubMed ID: 23645288
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of N-methylformamide.
McVie JG; ten Bokkel Huinink WW; Simonetti G; Dubbelman R
Cancer Treat Rep; 1984 Apr; 68(4):607-10. PubMed ID: 6325001
[TBL] [Abstract][Full Text] [Related]
11. A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation.
Fyfe D; Raynaud F; Langley RE; Newell DR; Halbert G; Gardner C; Clayton K; Woll PJ; Judson I; Carmichael J
Cancer Chemother Pharmacol; 2002 Jan; 49(1):1-6. PubMed ID: 11855748
[TBL] [Abstract][Full Text] [Related]
12. N-methylformamide: cytotoxic, radiosensitizer, or chemosensitizer.
Clagett-Carr K; Sarosy G; Plowman J; Hoth DF; Leyland-Jones B
J Clin Oncol; 1988 May; 6(5):906-18. PubMed ID: 3284976
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of oral N-methylformamide in three phase II trials: a report from the National Cancer Institute of Canada Clinical Trials Group.
Eisenhauer EA; Weinerman BH; Kerr I; Quirt I
Cancer Treat Rep; 1986 Jul; 70(7):881-3. PubMed ID: 3719579
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
15. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
17. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial and clinical pharmacology of elsamitrucin.
Raber MN; Newman RA; Newman BM; Gaver RC; Schacter LP
Cancer Res; 1992 Mar; 52(6):1406-10. PubMed ID: 1540949
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule.
Fyfe D; Price C; Langley RE; Pagonis C; Houghton J; Osborne L; Woll PJ; Gardner C; Baguley BC; Carmichael J;
Cancer Chemother Pharmacol; 2001 Apr; 47(4):333-7. PubMed ID: 11345650
[TBL] [Abstract][Full Text] [Related]
20. Effects of sequential combinations of N-methylformamide with adriamycin on cultured melanoma cells (M14).
Arancia G; Molinari A; Calcabrini A; Citro G; Villa AM; Verdina A; Zupi G
Exp Mol Pathol; 1994 Feb; 60(1):12-26. PubMed ID: 8162967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
